Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 10
Submit an article Journal homepage
247
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816

Chul S. HaDepartment of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; Correspondence[email protected]
View further author information
,
Michael LeBlancSWOG Statistical Center; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; View further author information
,
Heiko SchöderDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; View further author information
,
Chelsea C. PinnixDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; ORCID Iconhttp://orcid.org/0000-0003-3982-3664View further author information
ORCID Icon,
Nancy L. BartlettDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA; ORCID Iconhttp://orcid.org/0000-0001-8470-394XView further author information
ORCID Icon,
Andrew M. EvensDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA; View further author information
,
Eric D. HsiDepartment of Pathology, Cleveland Clinic, Cleveland, OH, USA; View further author information
,
Lisa RimszaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA; View further author information
,
Michael V. KnoppDepartment of Radiology, The Ohio State University, Columbus, OH, USA; View further author information
,
Jun ZhangDepartment of Radiology, The Ohio State University, Columbus, OH, USA; View further author information
,
John P. LeonardDepartment of Medicine, Weill Cornell Medical Center, New York, NY, USA; View further author information
,
Brad S. KahlDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA; View further author information
,
Hongli LiSWOG Statistical Center; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; View further author information
,
Sonali SmithDepartment of Medicine, University of Chicago, Chicago, IL, USA; View further author information
,
Louis S. ConstineDepartment of Radiation Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA; View further author information
&
Jonathan W. FriedbergDepartment of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, NY, USAView further author information
 show all
Pages 2442-2447 | Received 05 Feb 2020, Accepted 08 May 2020, Published online: 26 May 2020

References

  • Specht L. Does radiation have a role in advanced stage Hodgkin’s or Non-Hodgkin Lymphoma? Curr Treat Options Oncol. 2016;17(1):4.
  • Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003;348(24):2396–2406.
  • Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29(32):4234–4242.
  • Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol. 1998;16(3):818–829.
  • Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–1799.
  • Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–4554.
  • Press OW, Li H, Schoder H, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816. J Clin Oncol. 2016;34(17):2020–2027.
  • Stephens DM, Li H, Schoder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach for stage III/IV Hodgkin lymphoma. Blood. 2019;134(15):1238–1246.
  • Kriz J, Reinartz G, Dietlein M, et al. Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys. 2015;92(1):46–53.
  • Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75(1):45–49.
  • Diefenbach CS, Connors JM, Friedberg JW, et al. Hodgkin lymphoma: current status and clinical trial recommendations. J Natl Cancer Inst. 2017;109(4). doi:10.1093/jnci/djw249
  • Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202–215.
  • Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 Trial. J Clin Oncol. 2018;36(5):454–462.
  • Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419–2429.
  • Ricardi U, Levis M, Evangelista A, et al. Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial. Radiother Oncol. 2019;133:s258–S259.
  • Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017;18(4):454–463.
  • Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–862.
  • Hsi ED, Li H, Nixon AB, et al. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019;133(16):1762–1765.
  • Schoder H, Moskowitz C. Metabolic tumor volume in lymphoma: hype or hope? J Clin Oncol. 2016;34(30):3591–3594.
  • Rossi C, Kanoun S, Berriolo-Riedinger A, et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med. 2014;55(4):569–573.
  • Guo B, Tan X, Ke Q, et al. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis. PLoS One. 2019;14(1):e0210224.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.